Skip to main content

Lambert-Eaton Myasthenic Syndrome News

Related terms: Lambert-Eaton Syndrome, Eaton-Lambert Syndrome, LEMS

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse Expanding Patient Population to Include Pediatric Patients

Firdapse is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. ("Catalyst")...

FDA Approves Ruzurgi (amifampridine) for Children with Lambert-Eaton Myasthenic Syndrome

May 06, 2019 – The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17...

FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome

November 28, 2018 – The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Autoimmune Disorders